KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for ClearPoint Neuro (CLPT) over the last 13 years, with Q3 2025 value amounting to -$3.3 million.

  • ClearPoint Neuro's Free Cash Flow fell 17415.36% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.9 million, marking a year-over-year decrease of 5573.02%. This contributed to the annual value of -$9.3 million for FY2024, which is 3575.54% up from last year.
  • As of Q3 2025, ClearPoint Neuro's Free Cash Flow stood at -$3.3 million, which was down 17415.36% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, ClearPoint Neuro's Free Cash Flow registered a high of -$1.2 million during Q4 2023, and its lowest value of -$6.4 million during Q1 2025.
  • Moreover, its 5-year median value for Free Cash Flow was -$3.4 million (2021), whereas its average is -$3.4 million.
  • In the last 5 years, ClearPoint Neuro's Free Cash Flow surged by 6166.24% in 2023 and then crashed by 17415.36% in 2025.
  • Quarter analysis of 5 years shows ClearPoint Neuro's Free Cash Flow stood at -$3.6 million in 2021, then grew by 13.54% to -$3.1 million in 2022, then skyrocketed by 61.66% to -$1.2 million in 2023, then tumbled by 30.76% to -$1.6 million in 2024, then crashed by 113.37% to -$3.3 million in 2025.
  • Its last three reported values are -$3.3 million in Q3 2025, -$2.6 million for Q2 2025, and -$6.4 million during Q1 2025.